Filing Flows › Comparisons › AVTX vs CLNN
Avalo Therapeutics vs Clene: AVTX and CLNN compared
Avalo Therapeutics is the larger company: $59K of revenue in its latest quarter (Q4 2025) against $56K for Clene (Q3 2026). Clene is growing faster (+273% against -69% a year earlier).
Where the money goes: AVTX and CLNN
Avalo Therapeutics (AVTX) · Q4 2025
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
Clene (CLNN) · Q3 2026
Clene, Q3 2026: revenue $56K (+273% year over year), net earnings $3.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Avalo Therapeutics (AVTX) | Clene (CLNN) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q3 2026 |
| Revenue | $59K | $56K |
| Revenue growth, Y/Y | -69% | +273% |
| Operating margin | n/m | n/m |
| Net earnings | −$13.7M | $3.9M |
| Operating cash flow | −$14.2M | −$4.6M |
| Market value | $595M | — |
| Analysts’ mean target | $36.60 | — |
Where the revenue comes from
Clene
- Product: $43K (77%)
- Royalty: $13K (23%)
Questions
Which is bigger, Avalo Therapeutics or Clene?
Avalo Therapeutics is the larger company: $59K of revenue in its latest quarter (Q4 2025) against $56K for Clene (Q3 2026).
Is Avalo Therapeutics or Clene growing faster?
Clene is growing faster (+273% against -69% a year earlier).
More: Avalo Therapeutics earnings · how Avalo Therapeutics makes money · Clene earnings · how Clene makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 23, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.